Hagop M. Kantarjian, MD, of MD Anderson Cancer Center, discusses a study that compared efficacy and safety results of using 5-day and 10-day regimens of a novel hypomethylating agent in 103 treatment-naïve AML patients who were not candidates for intensive chemotherapy (Abstract 458).
Richard M. Stone, MD, of the Dana-Farber Cancer Institute, discusses this international prospective study on the survival impact of midostaurin, a multikinase inhibitor, in newly d...
Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, and Stephan Stilgenbauer, MD, PhD, of the University of Ulm, discuss this late-breaking abs...
Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and John F. Gerecitano, MD, PhD, of Memorial Sloan Kettering Cancer Center, discuss a phase I st...
Kieron Dunleavy, MD, of the National Cancer Institute, discusses a multi-center trial that set out to validate the effectiveness of DA-EPOCH-R-based therapy and whether a risk-adap...
Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and Cameron J. Turtle, MBBS, PhD, of the Fred Hutchinson Cancer Research Center, discuss anti-CD...